You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
17 search results for: airway remodeling
expert video
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of AirwayRemodeling?
Pulmonology
Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airwayremodeling and discusses practical aspects of identifying and managing airwayremodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.
ERS 2024 | AirwayRemodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Pulmonology
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airwayremodeling and its impact on patients with severe asthma.
ADVENT On Air | Diving Deep: Exploring the Impact of AirwayRemodeling in Severe Asthma
Pulmonology
Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airwayremodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.
Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type 2 inflammation contributes to key symptoms of inflammatory diseases across organs
Association of Younger Age of Onset With Persistence of AD
Dermatology
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.